Samsung Bioepis Co. Ltd. and partner Biogen Inc. have settled patent litigation with AbbVie Inc. surrounding Imraldi SB5 a biosimilar of AbbVie's Humira adalimumab. Under the settlement SamsungBiogen get nonexclusive rights to AbbVie's Humirarelated intell...
↧